⚗️ biochemistry

Structural basis for the unexpected activity of rifamycin B against rifampicin-resistant RNA polymerase

This study reveals the structural basis for Rifamycin B's ability to inhibit rifampicin-resistant RNA polymerase, demonstrating that its unique C-4 O-carboxymethyl group forms a stabilizing salt bridge with the enzyme that bypasses common resistance mutations, thereby identifying a new target for rational antibiotic design.

Original authors: Mosaei, H., Shin, Y., Kozhevnikov, V. N., Waddell, P. G., Hall, M. J., Murakami, K. S., Zenkin, N.

Published 2026-07-14

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Mosaei, H., Shin, Y., Kozhevnikov, V. N., Waddell, P. G., Hall, M. J., Murakami, K. S., Zenkin, N.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine bacterial RNA polymerase (RNAP) as a busy factory machine that builds the blueprints for life. For decades, doctors have used a powerful antibiotic called rifampicin to jam this machine, stopping bacteria from copying their instructions. But the bacteria are sneaky; they've started building tiny shields around the machine's "jamming spot," making the drug useless. This is the rise of drug resistance.

Enter Rifamycin B (Rif B). Think of this as the "grandparent" of the rifampicin family. It was discovered early on but mostly ignored because it seemed a bit wobbly (chemically unstable) and not very strong at killing bacteria. Scientists assumed it was just a messy, unstable step on the way to making better drugs, and they moved on.

But this paper says, "Wait a minute! Let's take a closer look."

The Big Surprise: The Wobbly Grandparent is Still Strong
The authors first checked if Rif B was actually too unstable to be useful. They watched it in a test tube for 16 hours at body temperature (37°C). The result? It stayed mostly itself. It didn't fall apart fast enough to mess up the experiment. So, the "wobbly" reputation wasn't the whole story.

Next, they tested it against the "shielded" bacteria machines (those with resistance mutations). Usually, rifampicin bounces right off these shields. But Rif B? It didn't just bounce; it stuck!

Against one specific shield (the βS531L mutation), Rif B was 30 times more effective than rifampicin.
Against another (βD516Y), it was 40 times better.
And against a third (βH526Y), where rifampicin failed completely (even at high doses of 2.5 mg/mL), Rif B still managed to jam the machine.

The Secret Weapon: A New Hook
How did it do this? The team built a 3D map (a crystal structure) of Rif B and saw exactly how it fits into the machine.

Think of the machine's jamming pocket like a glove. Rifampicin fits in the glove, but if the bacteria changes the shape of the fingers (mutations), the glove becomes too loose, and the drug falls out.

Rif B, however, has a special extra piece: a little tail at position C-4 (a carboxymethyl group).

In the free molecule: This tail curls up and hugs itself, like a cat sleeping in a ball.
When it binds to the machine: That tail uncurls and grabs onto a specific part of the machine called "fork loop 2" (specifically an arginine residue, R540). It forms a strong salt bridge—a chemical handshake—that locks the drug in place.

This extra handshake is the magic. Even when the bacteria tries to change the shape of the glove to kick out rifampicin, Rif B holds on tight with this second hand. The paper suggests this extra grip is why it works on resistant strains.

What This Means (and What It Doesn't)
The authors are careful to say this doesn't mean Rif B is the next miracle cure for tuberculosis right now. It's still chemically tricky and not as potent as modern drugs in general. But, this discovery changes how we see the drug family.

They argue that we shouldn't just view Rif B as a broken-down intermediate or a "failed" version of rifampicin. Instead, it's a unique tool with a specific trick (that C-4 tail) that modern drugs lost when they tried to make the molecule more stable.

The paper suggests that future drug designers might want to look at this C-4 tail again. Maybe we can build new drugs that keep this special "handshake" feature to fight back against the super-resistant bacteria. It's a reminder that sometimes, the "old" or "imperfect" things in nature hold secrets we missed because we were too busy looking for the "perfect" version.

The Bottom Line
The paper proves that Rifamycin B is stable enough to study and surprisingly effective against resistant bacteria because it uses a unique chemical hook that modern drugs don't have. It's not a solved problem for medicine yet, but it opens a new door for designing better drugs in the future.

Problem Statement
Rifamycins are critical antibiotics that inhibit bacterial transcription by binding to the RNA polymerase (RNAP) $\beta$ -subunit. However, their clinical utility is severely compromised by the rapid emergence of resistance, primarily driven by point mutations in the rpoB gene (encoding the $\beta$ -subunit) that alter the drug-binding pocket. While semisynthetic derivatives like rifampicin are widely used, they are ineffective against many resistant variants. Rifamycin B (Rif B), an early natural product and precursor to these derivatives, has historically been overlooked due to its chemical instability in aqueous solutions and perceived weak antibacterial activity. Consequently, its structural properties and potential efficacy against rifampicin-resistant RNAP variants remain poorly characterized, leaving a gap in understanding whether its unique C-4 O-carboxymethyl substituent offers any functional advantage over downstream derivatives.

Methodology
The authors employed a multidisciplinary approach combining structural biology, biochemistry, and mass spectrometry:

Structural Characterization: The team determined the first single-crystal X-ray structure of unmodified Rif B to establish its baseline conformation. They also solved the crystal structure of the Rif B–Thermus thermophilus RNAP $\sigma^A$ holoenzyme complex.
Chemical Stability Analysis: Using LC–MS, the authors monitored the chemical conversion of Rif B into its derivatives (Rif O, Rif S, Rif SV) under assay conditions to confirm that observed biological effects were attributable to Rif B itself rather than degradation products.
Biochemical Assays: In vitro transcription assays were performed using wild-type E. coli RNAP and variants carrying clinically relevant rifampicin-resistance mutations ( $\beta$ S531L, $\beta$ D516Y, $\beta$ H526Y, $\beta$ I572F). Dose-response curves were generated to calculate half-maximal inhibitory concentrations (IC $_{50}$ ) for both Rif B and rifampicin.

Key Results

Stability: LC–MS analysis confirmed that while Rif B undergoes slow conversion to other derivatives over time, it remains the predominant species under the conditions used for biochemical assays (16 hours at 37°C), validating that the observed activity is intrinsic to Rif B.
Inhibitory Activity: Rif B inhibits wild-type RNAP with potency comparable to rifampicin. Crucially, Rif B retains significant inhibitory activity against all tested rifampicin-resistant RNAP variants. The difference was most pronounced for the $\beta$ S531L and $\beta$ D516Y mutants, where Rif B was approximately 30-fold and 40-fold more active than rifampicin, respectively. Notably, while rifampicin showed no inhibition against the $\beta$ H526Y mutant even at high concentrations, Rif B retained activity against this variant.
Structural Insights:
- Apo Structure: In the free state, the C-4 O-carboxymethyl group of Rif B forms an intramolecular hydrogen bond with the C-11 carbonyl, creating a ten-membered ring.
- Bound Structure: Upon binding to RNAP, this intramolecular interaction is replaced by a salt bridge between the C-4 O-carboxymethyl group and the arginine residue at position 540 (R540) of the $\beta$ -subunit's fork loop 2.
- Mechanism of Resistance Evasion: This additional interaction with fork loop 2 is absent in rifampicin. The authors propose that this salt bridge stabilizes fork loop 2, preventing the conformational changes (specifically the "opening" of the loop) associated with resistance mutations like S531L, thereby maintaining drug efficacy.

Significance and Claims
The paper redefines Rif B not merely as an unstable precursor or degradation-prone intermediate, but as a distinct rifamycin scaffold with a unique mechanism of action. The primary contribution is the identification of the C-4 O-carboxymethyl substituent as a functional element that confers reduced sensitivity to resistance-associated mutations through a specific salt bridge with $\beta$ R540.

The authors claim that these findings:

Provide the first atomic-level structural basis for the activity of unmodified Rif B.
Demonstrate that a chemical feature historically associated with reduced antibacterial activity (the C-4 carboxyl group) actually provides a critical interaction for target binding.
Identify the C-4 position as an underexplored site for rational drug design. The authors suggest that preserving or modifying this interaction (e.g., by introducing groups that engage the $\sigma$ region 3.2) could lead to new derivatives capable of overcoming rifampicin resistance, offering a new direction for developing inhibitors against resistant bacterial strains.

More like this